Suggestions
Mikael Eliasson
Global Head Innovation, Neuroscience Genentech/Roche - New Business Creation - Digital Health - Pills Don't Teach Skills - Neurotech
Professional Background
Mikael Eliasson is a highly esteemed physician-scientist whose impressive career spans over two decades in the biotechnology, meditech, and diagnostics sectors. With a powerful track record for transforming innovative ideas into lucrative billion-dollar businesses, Mikael has held senior executive positions at some of the industry’s leading companies, including Roche, Novartis, and GE Healthcare. He possesses a unique ability to connect various domains of expertise, acting as an "innovation catalyst" that brings together diverse groups of people to foster groundbreaking ideas that generate significant results in highly competitive markets.
Mikael's leadership roles are a testament to his deep understanding of both the scientific and business aspects of medicine. His tenure as the Global Head of Innovation for Neuroscience Product Development at Roche demonstrates his commitment to forward-thinking strategies that prioritize patient outcomes while pushing the boundaries of scientific research.
His career began at The Johns Hopkins University, where he pursued both his MD and PhD, which laid the foundation for his future endeavors in medicine and science. Armed with this rigorous education, he carved a path through various executive roles in healthcare companies, where he was instrumental in generating strategic innovations and overseeing the development of groundbreaking medical products.
In his capacity as Global Transformation Leader for GE Healthcare Marketing, Mikael showcased his strength in aligning innovative projects with the broader strategic goals of the organization to ensure effective marketing strategies. His dynamic leadership helped the company thrive in an ever-changing healthcare landscape.
Education and Achievements
Mikael Eliasson’s educational journey is rooted in the rigorous and competitive environments of prestigious institutions. He holds a Bachelor of Arts degree from Harvard University, which served as an invaluable starting point for his medical career. His subsequent studies at The Johns Hopkins University School of Medicine culminated in both a Doctor of Medicine (M.D.) and a Doctor of Philosophy (Ph.D.), highlighting his unwavering dedication to science and medicine.
This combination of degrees from such highly respected institutions attests to his expertise in medical research, equipping him with an in-depth understanding of clinical practice and the scientific method. His academic background uniquely positions him to bridge the gap between innovative medical research and practical application within the industry, enabling him to drive business transformation and innovation.
Notable Achievements
Mikael is known for his strong record of achievements in various capacities throughout his career. At Novartis, he served as the Global Head of New Products for both Critical Care and Cardiovascular & Metabolism, where he aligned product strategies with evolving patient needs, ensuring the company remained competitive in these critical therapeutic areas. His strategies not only boosted product placement but also significantly enhanced market accessibility for life-changing treatments.
As VP Global Change Leader at The Medicines Company, Mikael played a pivotal role in navigating change management processes and fostering a culture of innovation that empowered his team to take risks and innovate thoughtfully. His contributions have consistently produced actionable outcomes that contributed to each organization’s overarching goals.
Mikael's role as a Principal at Monitor Ventures and as a Consultant at Monitor Group allowed him to apply his expertise across various projects, influencing multiple sectors within healthcare. His collaborations with leading healthcare firms and startups exhibit his passion for pioneering groundbreaking solutions.
Through his tenure with organizations such as Roche and Novartis, Mikael has proven to be an invaluable asset, steering product development processes and enhancing strategic planning initiatives. His remarkable ability to comprehend and integrate multidisciplinary approaches has earned him respect and recognition among peers and industry leaders alike.
